ผลการใช้ G-CSF ป้องกันภาวะเม็ดเลือดขาวต่ำ ในการรักษาเสริมด้วยยาเคมีบำบัดสูตร TAC ในโรงพยาบาลนครปฐม

บทคัดย่อ

Background: TAC is highly effective regimen but has high incidence of febrile neutropenia more than 20%. This study is to review the safety profile of TAC regimen with and without using primary prophylactic G-CSF (PPG)

Patients and methods: From January 2005 - November 2007, thirty patients were received TAC as adjuvant treatment in node positive breast cancer at Nakhonpathom hospital. The patients were divided equally into 2 groups, first group was received TAC regimen as adjuvant chemotherapy without PPG and the second group was received TAC regimen as adjuvant chemotherapy with PPG. Age, size of tumor, lymph node involvement, doses received and toxicities were recorded.

Results: The using of G-CSF from the first cycle (PPG) reduced the incidence of neutropenia in patients treated with TAC (46.67% vs. 2.22%) and reduced the incidence of febrile neutropenia in patients treated with TAC (6.67% vs. 0%). PPG also improved the compliance of TAC regimen. The percentage of patients who did not delayed receiving TAC increased from 91.11% to 97.77% in the patients who received PPG.

Conclusions: This review shows that PPG reduces the incidence of neutropenia, neutropenic fever and improved the compliance of adjuvant TAC regimen. TAC is highly effective adjuvant treatment and with G-CSF support, has acceptable safety profile.